Advanced antisense therapies for postexposure protection against lethal filovirus infections.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20729866.
- Also identified by DOI 10.1038/nm.2202.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30-60 min after infection, protects>60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
Medical subject headings
- Filoviridae Infections
- Vaccines, Synthetic
- Viral Vaccines